{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:20:46Z","timestamp":1788182446045,"version":"build-2803163510"},"reference-count":29,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:p>Background: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and currently lacks defined therapeutic targets. Although miR-152-3p functions as a tumor suppressor in various cancers, its specific mechanism and regulatory network in TNBC remain poorly understood. Objectives: To investigate the expression and tumor-suppressive function of miR-152-3p in TNBC cells and to elucidate its mechanism of targeting STAT3, RELA and ADCY6. Methods: miR-152-3p expression was compared between MDA-MB-231 and MCF-10A cells using qRT-PCR. MDA-MB-231 cells were transfected with miR-152-3p mimics or inhibitors and cell proliferation, apoptosis and invasion were assessed by MTT assay, flow cytometry and Transwell assay, respectively. Direct target interactions were validated by a dual-luciferase reporter assay, and protein levels of STAT3, RELA, and ADCY6 were examined by Western blot. Key findings were further validated in Hs 578T cells. Results: miR-152-3p expression was significantly downregulated in TNBC cells. Overexpression of miR-152-3p markedly inhibited proliferation and invasion while promoting apoptosis in MDA-MB-231 cells. Dual-luciferase reporter assays confirmed that miR-152-3p directly binds to the 3\u2018untranslated regions of STAT3, RELA and ADCY6. Overexpression of miR-152-3p significantly reduced STAT3 and RELA protein levels while upregulating ADCY6 expression. Rescue experiments demonstrated that restoration of STAT3 expression partially reversed the tumor-suppressive effects of miR-152-3p. These findings were recapitulated in Hs 578T cells, suggesting generalizability across TNBC subtypes. Conclusion: miR-152-3p suppresses TNBC progression by downregulating STAT3\/RELA and upregulating ADCY6, thereby activating cAMP signaling. These findings provide a foundation for further investigation into the potential of miR-152-3p as a multi-target therapeutic strategy for TNBC.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.7.202.1","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:59:46Z","timestamp":1779361186000},"source":"Crossref","is-referenced-by-count":0,"title":["MiR-152-3p Inhibits Triple-Negative Breast Cancer Cell Progression By Targeting Signal Transducer And Activator Of Transcription 3, Nuclear Factor Kappa B Subunit P65 And Adenylate Cyclase 6"],"prefix":"10.36721","author":[{"given":"Yan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Arun S, Patel PK, Lakshmanan K, Rajangopal K, Swaminathan G and Byran G (2024). Targeting STAT3 enzyme for cancer treatment. Mini Rev Med Chem., 24(13): 1252\u20131261.","DOI":"10.2174\/0113895575254012231024062619"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Billi M, De Marinis E, Gentile M, Nervi C and Grignani F (2024). Nuclear miRNAs: Gene regulation activities. Int J Mol Sci., 25(11): 6066.","DOI":"10.3390\/ijms25116066"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Calaf GM, Crispin LA and Quisbert-Valenzuela EO (2024). Noscapine and apoptosis in breast and other cancers. Int J Mol Sci., 25(6): 3536.","DOI":"10.3390\/ijms25063536"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Campolo F, Capponi C, Tarsitano MG, Tenuta M, Pozza C, Gianfrilli D, Magliocca F, Venneri MA, Vicini E, Lenzi A, Isidori AM and Barbagallo F (2022). cAMP-specific phosphodiesterase 8A and 8B isoforms are differentially expressed in human testis and Leydig cell tumor. Front Endocrinol (Lausanne)., 13: 1010924.","DOI":"10.3389\/fendo.2022.1010924"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Deng L, Liao L, Zhang YL, Yang SY, Hu SY andriani L, Ling YX, Ma XY, Zhang FL, Shao ZM and Li DQ (2024). SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1. Sci Adv., 10(14): eadj4009.","DOI":"10.1126\/sciadv.adj4009"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Dong C, Sun Y, Xu X, Li H, Song X, Wei W, Jiao C, Xu H, Liu Y, Mierzhakenmu Z, Li L and Ma B (2025). c-Myc knockdown restores tamoxifen sensitivity in triple-negative breast cancer by reactivating the expression of ER\u03b1: the central role of miR-152 and miR-148a. Breast Cancer., 32(3): 529\u2013542.","DOI":"10.1007\/s12282-025-01683-w"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Du C, Zhang J, Zhang L, Zhang Y, Wang Y and Li J (2021). Hsa_circRNA_102229 facilitates the progression of triple-negative breast cancer via regulating the miR-152-3p\/PFTK1 pathway. J Gene Med., 23(9): e3365.","DOI":"10.1002\/jgm.3365"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ethiraj P, Sasi B, Holder KN, Lin AP, Qiu Z, Jaafar C, Elkhalili A, Desai P, Saksena A, Ritter JP and Aguiar RCT (2022). Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1\u03b1 intersect to regulate angiogenesis in B-cell lymphoma. Br J Haematol., 198(2): 349\u2013359.","DOI":"10.1111\/bjh.18196"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gao Z, Lei WI and Lee LTO (2022). The role of neuropeptide-stimulated cAMP-EPACs signalling in cancer cells. Molecules., 27(1): 311.","DOI":"10.3390\/molecules27010311"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A and Siegel RL (2024). Breast cancer statistics 2024. CA Cancer J Clin., 74(6): 477\u2013495.","DOI":"10.3322\/caac.21863"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Guo R, Liu T, Shasaltaneh MD, Wang X, Imani S and Wen Q (2022). Targeting adenylate cyclase family: New concept of targeted cancer therapy. Front Oncol., 12: 829212.","DOI":"10.3389\/fonc.2022.829212"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Hu Y, Dong Z and Liu K (2024). Unraveling the complexity of STAT3 in cancer: Molecular understanding and drug discovery. J Exp Clin Cancer Res., 43(1): 23.","DOI":"10.1186\/s13046-024-02949-5"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Kainat N, Mansoor Q and Baig RM (2026). SNP-Driven LncRNA H19 dysregulation and CeRNA axis in breast and thyroid cancers among Pakistani females. Mol Biol Rep., 53(1):409.","DOI":"10.1007\/s11033-026-11565-9"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Leon-Ferre RA and Goetz MP (2023). Advances in systemic therapies for triple negative breast cancer. BMJ., 381: e071674.","DOI":"10.1136\/bmj-2022-071674"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Mufidah N, Muzari K, Budi HS, Indrawati R, Anitasari S, Shen YK and Umarudin U (2025). Oral anticancer promising of hexadecanoic acid through melecular interaction to nuclear factor-kappa-B p65\/RELA and tumor suppressor-p53. Braz J Biol., 85: e287760.","DOI":"10.1590\/1519-6984.287760"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Ning N, Tian Z, Feng H and Feng X (2024). Lnc NEAT1 facilitates the progression of melanoma by targeting the miR-152-3p\/CDK6 axis: An observational study. Medicine (Baltimore)., 103(44): e40379.","DOI":"10.1097\/MD.0000000000040379"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Patritti Cram J, Wu J, Coover RA, Rizvi TA, Chaney KE, Ravindran R, Cancelas JA, Spinner RJ and Ratner N (2022). P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation and nerve tumor initiation in a mouse model of neurofibromatosis. Elife., 11: e73511.","DOI":"10.7554\/eLife.73511"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Sammons SL, Sanglier T, Leone JP, Erick TK, Lambert P, Montemurro F, Poppe R, Restuccia E, Tolaney SM and Lin NU (2025). Prevalence by therapy line and incidence of breast cancer brain metastases in 18\u2009075 patients. J Natl Cancer Inst., 117(8): 1565\u20131572.","DOI":"10.1093\/jnci\/djaf048"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Shao X, Meng X, Yang H, Wang X, Qin L, Shen G, Xi X, Zhao H, Macip S and Chen Y (2023). IFN-\u03b3 enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway. Leuk Lymphoma., 64(1): 71\u201378.","DOI":"10.1080\/10428194.2022.2131408"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Sun Y, An L, Kong L, Liu X, Zhang H, Liu J and Qian P (2025). MiR-518c-5p\/miR-4524a-3p can mediate immune escape and chemotherapy resistance in triple-negative breast cancer and predict its outcome. Hereditas., 162(1): 216.","DOI":"10.1186\/s41065-025-00572-8"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Turijan-Espinoza E, Ruiz-Rodriguez VM, Paz-Rodriguez VA, Hernandez-Hernandez GE, Hernandez-Gonzalez O, Guel-Panola JA, Zermeno-Nava JJ, Gutierrez-Gil MC and Portales-Perez DP (2026). Profiles of microRNAs in patients with advanced breast cancer who are chemoresistant or chemosensitive to fluorouracil, adriamycin and cyclophosphamide treatment. Asian Pac J Cancer Prev., 27(2):469\u2013479.","DOI":"10.31557\/APJCP.2026.27.2.469"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Wu J, Xu W, Ma L, Sheng J, Ye M, Chen H, Zhang Y, Wang B, Liao M, Meng T, Zhou Y and Chen H (2021). Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195\/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer. Aging (Albany NY)., 13(14): 18191-18222.","DOI":"10.18632\/aging.203156"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Yang B, Huang S, Chen H, Li R, Hou S, Zhao J and Li Y (2022). DNMT3B regulates proliferation of A549 cells through the microRNA-152-3p\/NCAM1 pathway. Oncol Lett., 23(1): 11.","DOI":"10.3892\/ol.2021.13129"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Yin T and Zhao H (2022). miR-152-3p impedes the malignant phenotypes of hepatocellular carcinoma by repressing roundabout guidance receptor 1. Cell Mol Biol Lett., 27(1): 22.","DOI":"10.1186\/s11658-022-00322-y"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Zeng X, Ma X, Guo H, Wei L, Zhang Y, Sun C, Han N, Sun S and Zhang N (2021). MicroRNA-582-5p promotes triple-negative breast cancer invasion and metastasis by antagonizing CMTM8. Bioengineered., 12(2): 10126-10135.","DOI":"10.1080\/21655979.2021.2000741"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L and Yan Q (2022). CECR2 drives breast cancer metastasis by promoting NF-\u03baB signaling and macrophage-mediated immune suppression. Sci Transl Med., 14(630): eabf5473.","DOI":"10.1126\/scitranslmed.abf5473"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Zhang Z, Li B, Wu S, Yang Y, Wu B, Lai Q, Lai F, Mo F, Zhong Y, Wang S, Guo R and Zhang B (2024). Bergenin protects against osteoarthritis by inhibiting STAT3, NF-\u03baB and Jun pathways and suppressing osteoclastogenesis. Sci Rep., 14(1): 20292.","DOI":"10.1038\/s41598-024-71259-9"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Zhou X, Zhao J, Yan T, Ye D, Wang Y, Zhou B, Liu D, Wang X, Zheng W, Zheng B, Qian F, Li Y, Li D and Fang L (2024). ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway. Cell Death Dis., 15(4): 260.","DOI":"10.1038\/s41419-024-06643-4"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Zuo X, Zhao X, Zhang X, Li Q, Jiang X, Huang S, Chen X, Chen X, Jia W, Zou H, Shi D and Qian X (2024). PTPN20 promotes metastasis through activating NF-\u03baB signaling in triple-negative breast cancer. Breast Cancer Res., 26(1): 155.","DOI":"10.1186\/s13058-024-01910-w"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:56:26Z","timestamp":1788180986000},"score":1,"resource":{"primary":{"URL":"https:\/\/pjps.pk\/single-article?id=7805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":29,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.7.202.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}